Tapestry is patented and has been licensed by DCGI and CDSCO has given the green light for commercial use as an unregulated medical device
The Indian Institute of Technology, Bombay (IITB) has invented an ingenious Tapestry covid test method. Tapestry is a technology that enables the safe reopening of workplaces and education using affordable and frequent testing using a single quantitative clustering algorithm with the benchmark RT-qPCR test.
Tapestry’s patented technology was developed with the help of leading research institutions such as the National Center for Biological Sciences (NCBS), Institute for Stem Cell Science and Regenerative Medicine (InStem), Tata Memorial Center , the Center for Cellular & Molecular Biology (CCMB) and renowned international research laboratories. Its innovative approach has been highlighted by articles in leading international scientific forums such as Nature, the IEEE newsletter, SIAM news, AMS news, etc. Tapestry has been named by the XPRIZE Pandemic Alliance as one of 10 finalists in the XPRIZE Rapid Covid Testing competition, a global COVID-19 Testing Competition designed to create high-quality, affordable COVID-19 tests to help society reopen safely and resume daily activities.
âPolicymakers have been asked to make an impossible choice between health distress and economic distress. Tapestry is proposing a gradual and safe reopening so that we can enter a new world with more life and less Covid â, explains Prof. Manoj Gopalkrishnan, inventor of Tapestry and scientist-founder of ABPL. Bengaluru-based start-up Algorithmic Biologics Pvt Ltd (ABPL) has launched Tapestry, its first commercial product to step up covid testing.
Dr Gopalkrishnan is excited about the potential of using algorithmic innovations to improve molecular testing technologies not only in healthcare, but also in pharmaceutical, agricultural, animal, food safety, synthetic biology and research fields. in molecular biology. According to him, such technologies are a first step on the journey of bringing intelligence to molecules and creating molecular technologies that can match the fertility of the biological world.
Tapestry’s platform technology works as a compression algorithm for molecular testing, like how JPEG or ZIP compression preserves all information but in a much smaller file size. Samples from different individuals are mixed into pools according to a code. Each sample is sent to three pools, ensuring triplicate tests and accurate results. Individual level results are retrieved by examining the clustering results model and applying a decoding algorithm.
Tapestry has been cleared by the Drugs Controller General of India (DCGI) for commercial use as an unregulated medical device and registered with the Central Drugs Standard Control Organization (CDSCO). Bengaluru-based start-up Algorithmic Biologics Pvt Ltd (ABPL) has launched Tapestry, its first commercial product to step up covid testing.